This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Increases speed to market for drug developers working on nucleic acid therapeutics
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Subscribe To Our Newsletter & Stay Updated
